/

Empresas

Ca

No verificado

Capsida Biotherapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa

12/05/2026

Mercado laboral

Eventos

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Capsida to Present Preclinical Data of New Next-Generation, High-Performing Ocular Capsids at ASGCT Annual Meeting

Fuente

Capsida Biotherapeutics

Editor

1.00

0

11/06/2025

Higiene alimentaria

Salud

Biotecnología

Farmacéutica

Medicina - Varios

Industria

Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated With GBA Mutations

Fuente

Capsida Biotherapeutics

Editor

1.00

0

29/05/2025

Salud

Higiene alimentaria

Biotecnología

Medicina - Varios

Farmacéutica

Industria

Capsida Receives FDA Fast Track Designation for Its Potential First-in-Class IV-Administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

Fuente

Capsida Biotherapeutics

Editor

1.00

0

14/05/2025

Industria

Salud

Biotecnología

Medicina - Varios

Ciencia

Farmacéutica

Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

Fuente

Capsida Biotherapeutics

Editor

1.00

0

12/05/2025

Biotecnología

Higiene alimentaria

Salud

Medicina - Varios

Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

Fuente

Capsida Biotherapeutics

Editor

1.00

0

28/04/2025

Web y redes sociales

Eventos

Salud

Biotecnología

Ciencia

Sanidad

Capsida to Present Progress Updates at the ASGCT Annual Meeting, Including NHP GLP Toxicology Study Results for its Potential First-in-Class STXBP1 Developmental and Epileptic Encephalopathy Program (CAP-002 STXBP1-DEE)

Fuente

Capsida Biotherapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0